ClinicalTrials.gg
Not yet recruitingNCT07794124EVOLUERAUpdated Aug 31, 2026

Evaluation of the FreeO2 System for Oxygen Weaning After Acute Hypoxemic Respiratory Failure

An interventional study of FreeO2 automated oxygen titration system and Standard oxygen weaning in Acute Hypoxemic Respiratory Failure and Hypoxemia, sponsored by Centre Hospitalier Universitaire de Besancon. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Centre Hospitalier Universitaire de Besancon · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Acute hypoxemic respiratory failure (AHRF) is a common condition associated with substantial morbidity, mortality, and healthcare resource utilization. Although advances in oxygen therapy, particularly high-flow nasal oxygen (HFNO), have improved the management of AHRF, the transition from HFNO to conventional low-flow oxygen therapy remains an important and understudied phase of patient care.

During oxygen weaning, oxygen flow is usually adjusted manually by healthcare professionals according to a target oxygen saturation (SpO₂). Because oxygen saturation is often assessed intermittently outside continuously monitored settings, patients may experience episodes of hypoxemia or hyperoxia before oxygen flow is adjusted.

FreeO2 is an automated oxygen titration system that continuously adjusts oxygen flow according to the patient's SpO₂. Its safety and effectiveness have been demonstrated in several clinical settings, but its use during oxygen weaning after HFNO has not been specifically evaluated.

The objective of this study is to assess whether the use of the FreeO2 system during oxygen weaning after HFNO in patients recovering from acute hypoxemic respiratory failure improves oxygen saturation control and facilitates the weaning process compared with standard oxygen therapy.

02

Conditions studied

  • Acute Hypoxemic Respiratory Failure
  • Hypoxemia

Keywords

  • Acute Hypoxemic Respiratory Failure
  • FreeO2
  • Oxygen Weaning
  • Automated Oxygen Titration
03

In context

Respiratory Insufficiency

1,369 studies on the registry are indexed under Respiratory Insufficiency; 264 are open to participants now.

This study's planned enrollment of 40 is below the median of 60 across 860 interventional studies indexed under Respiratory Insufficiency.

Browse Respiratory Insufficiency studies →

Lead sponsor

Centre Hospitalier Universitaire de Besancon is the lead sponsor of 450 studies on the registry; 97 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Acute hypoxemic respiratory failure requiring high-flow nasal oxygen therapy for at least 12 hours
  • Fraction of inspired oxygen (FiO₂) ≤35%
  • Peripheral oxygen saturation (SpO₂) ≥ the predefined lower target threshold:
  • 88% in patients at risk of hypercapnia
  • 94% in patients without risk of hypercapnia
  • Women of must use an effective method (oral contraceptives, injectable contraceptives, intrauterine device, double-barrier method, contraceptive patch); women must be for at least 24 months or surgically sterilized
  • Patient's oral agreement and absence of written refusal to participate, indicating that the participant has understood the study objectives and required procedures and agrees to participate and comply with study-related requirements and restrictions
  • Affiliation with or beneficiary of the French social security system

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Uncontrolled acute respiratory acidosis requiring invasive or non-invasive mechanical ventilation
  • Unstable peripheral oxygen saturation (SpO₂)
  • Excessive bronchial secretions
  • Carbon monoxide poisoning
  • Severe cardiocirculatory failure (mean arterial pressure \<65 mmHg without fluid resuscitation and/or requiring vasopressors, and/or severe arrhythmia)
  • Acute neurological failure (Glasgow Coma Scale \<15, or new-onset sensorimotor deficit)
  • Acute kidney injury requiring renal replacement therapy
  • Known untreated severe obstructive sleep apnea
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Participants assigned to the intervention group will undergo oxygen weaning using the FreeO2 automated oxygen titration system.

    Device: FreeO2 automated oxygen titration system

  • Active comparator
    Control group

    Participants will undergo standard oxygen weaning according to usual clinical practice, with oxygen flow adjusted manually based on target oxygen saturation.

    Other: Standard oxygen weaning

Interventions

  • DeviceFreeO2 automated oxygen titration system

    The FreeO2 system is an automated oxygen titration device that continuously adjusts oxygen flow according to the patient's peripheral oxygen saturation (SpO₂). In this study, the device will be used during oxygen weaning after high-flow nasal oxygen therapy in patients recovering from acute hypoxemic respiratory failure.

  • OtherStandard oxygen weaning

    Oxygen flow will be adjusted manually by healthcare professionals according to usual clinical practice and predefined target oxygen saturation levels.

06

What researchers measure

Primary outcomes

  1. Cumulative oxygen volume administered during the oxygen weaning period

    Time frame: From initiation of oxygen weaning until successful weaning (oxygen discontinuation or return to baseline oxygen requirements with stable oxygen flow for ≥4 hours).

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 359 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 375 studies reached it within 24 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2026
First posted
Aug 31, 2026
StartEst.
Sep 15, 2026
Primary completionEst.
Sep 15, 2027
CompletionEst.
Jan 1, 2028
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07794124
Responsible party
Sponsor
First posted
Aug 31, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Sep 15, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Aug 31, 2026

Study contacts

Lucie Laurent, Clinical Research Coordinator
Contact
llaurent@chu-besancon.fr
+33381669293
Frédéric Claudé
principal investigator · CHU Besançon Franche-Comté

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion